Publications by authors named "Matthew D Hellmann"

Claim this Profile
A
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun, Matthew D Hellmann

Nature· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer.
Camila Robles-Oteíza, Katherine Hastings, Jungmin Choi, Isabelle Sirois, Arvind Ravi, Matthew D Hellmann

J Exp Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun, Matthew D Hellmann

Nature· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer.
Arielle Elkrief, Meagan Montesion, Smruthy Sivakumar, Caryn Hale, Anita S Bowman, Matthew D Hellmann

J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.
Gabriel Espinosa-Carrasco, Edison Chiu, Aurora Scrivo, Paul Zumbo, Asim Dave, Matthew D Hellmann

Cancer Cell· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy.
Arielle Elkrief, Eder Orlando Méndez-Salazar, Jade Maillou, Chad M Vanderbilt, Pooja Gogia, Matthew D Hellmann

NPJ Precis Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation.
Arielle Elkrief, Nicholas R Waters, Natalie Smith, Angel Dai, John Slingerland, Matthew D Hellmann

Cancer Immunol Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer.
Danish Memon, Adam J Schoenfeld, Darwin Ye, George Fromm, Hira Rizvi, Matthew D Hellmann

Cancer Cell· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
Sandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, Ding Wang, Jarushka Naidoo, Matthew D Hellmann

J Immunother Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
Rohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, Daniel Muldoon, Hira Rizvi, Matthew D Hellmann

Clin Cancer Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
Arielle Elkrief, Biagio Riccuiti, Joao V Alessi, Teng Fei, Hannah L Kalvin, Matthew D Hellmann

Oncologist· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation.
Charles M Rudin, David Balli, W Victoria Lai, Allison L Richards, Evelyn Nguyen, Matthew D Hellmann

J Thorac Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.
Martin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, Matthew A Gubens, Charu Aggarwal

Nat Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study.
Arielle Elkrief, Joao M Victor Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Matthew D Hellmann

J Immunother Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC.
Laurent Dercle, Matthew Fronheiser, Naiyer A Rizvi, Matthew D Hellmann, Sabine Maier

J Thorac Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
Arvind Ravi, Matthew D Hellmann, Monica B Arniella, Mark Holton, Samuel S Freeman

Nat Genet· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade.
Joy A Pai, Matthew D Hellmann, Jennifer L Sauter, Marissa Mattar, Hira Rizvi

Cancer Cell· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy.
Naiyer Rizvi, Foluso O Ademuyiwa, Z Alexander Cao, Helen X Chen, Robert L Ferris, Matthew D Hellmann

J Immunother Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ectonucleotidase CD39 identifies tumor-reactive CD8 T cells predictive of immune checkpoint blockade efficacy in human lung cancer.
Andrew Chow, Fathema Z Uddin, Michael Liu, Anton Dobrin, Barzin Y Nabet, Matthew D Hellmann

Immunity· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort.
Kanika Arora, Thinh N Tran, Yelena Kemel, Miika Mehine, Ying L Liu, Matthew D Hellmann

Cancer Discov· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.
Justin Jee, Emily S Lebow, Randy Yeh, Jeeban P Das, Azadeh Namakydoust, Matthew D Hellmann

Nat Med· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Widespread hypertranscription in aggressive human cancers.
Matthew Zatzman, Fabio Fuligni, Ryan Ripsman, Tannu Suwal, Federico Comitani, Matthew D Hellmann

Sci Adv· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer.
Rami S Vanguri, Jia Luo, Andrew T Aukerman, Jacklynn V Egger, Christopher J Fong, Matthew D Hellmann

Nat Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer.
Adam J Schoenfeld, Hira A Rizvi, Danish Memon, Narek Shaverdian, Matthew J Bott, Matthew D Hellmann

Clin Cancer Res· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
Biagio Ricciuti, Xinan Wang, Joao V Alessi, Hira Rizvi, Navin R Mahadevan, Matthew D Hellmann

JAMA Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis